Brand Name : Rapolax
Composition : Sirolimus
Strength availability : 1mg
Manufactured by : Taj India Pharma Ltd
Tab Count : 100 Tablets

Rapolax 1mg belongs to immunosuppressant agent required to prevent organ refusal in renal transplants, in concomitant use with corticosteroids and cyclosporine.
It is also needed to inhibit rejection in heart transplant and for immunosuppression for stem cell/bone marrow transplants.
Rapolax 1mg which is prescribed as prescription drug under supervision of medical practioners.


Indicated for the prophylaxis of organ refusal in patients aged 13 years or older diagnosed renal transplants.


Initiating treatment concomitant use with cyclosporine and corticosteroids
High immunologic risk :
The usual loading dose is <40 kg: 3 mg/m² ≥40 kg: 15 mg PO loading dose Sustenance dose of Rapolax is 5 mg/day PO if >40 kg and 1 mg/m²/day if <40 kg on day 2 and after that; produce trough levels between days 5 and 7.
Dose should be adapting to control trough concentrations within desired range based on clinical state and concomitant therapy; further dose adjustment should not be done sooner than 7-14 days following a dose adjustment
Combination therapy: For the first year, continuing transplantation, Rapolax should be used in interaction with cyclosporine and corticosteroids; cyclosporine may be initiated at 7 mg/kg/day in double doses with the dose modify to get trough concentrations; prednisone should be taken at a dose of 5 mg/day
Low-to-moderate immunologic risk :
The usual loading dose <40 kg: 3 mg/m² ≥40 kg: 6 mg PO loading dose Sustenance: 2 mg/day PO if ≥ 40 k g and 1 mg/m²/day if <40 kg on day 2 and thereafter; obtain trough levels between days 5 and 7
Dose should be adapting to control trough concentrations within desired range based on clinical state and concomitant therapy; further dose adjustment should not be done sooner than 7-14 days following a dose adjustment
Combination therapy: continuing transplantation, Rapolax should be used in interaction with cyclosporine and corticosteroids; may stops cyclosporine gradually over 4-8 weeks two to four months after transplant in patients with low immunologic risk, &Rapolax dose higher (serum concentrations of sirolimus may reduce following cyclosporine withdrawal)
Rapolax prescribed for therapy of lymphangioleiomyomatosis (LAM)
Initial prescribed dose: 2 mg/day PO given in 10-20 days and then monitor whole blood trough level
Over dosage :
If overdose occurs all should provide general supportive measures.


Sirolimus blocks the T-lymphocytes activation and multiplication which occurs in response to antigenic and cytokinin (Interleukin [IL]-2, IL-4, and IL-15) activated by a mechanism which is distinct from that of other immunosuppressants.
Sirolimus also prevents antibody production. In cells, sirolimus joints to the immunophilin, FK Binding Protein-12 (FKBP-12), to produce an immunosuppressive complex. Sirolimus consist of FKBP-12 complex has no effect on calcineurin activity. This complex link to and prevents the activation of the mammalian target of rapamycin (mTOR), a key regulatory kinase. This prevention suppresses cytokine-driven T-cell replication, preventing the progression from the G1 to the S phase of the cell cycle.


The high plasma concentration is 1-2 hours in healthy patients and renal transplant patients and bioavailability are 27%. The drug has serum protein binding is 92%
Rapolax is widely metabolized in the intestinal wall and liver. It is substrate for both CYP3A4 and P-gp
Most of radioactivity was recovered from the faces is 91% and only little amount was excreted in urine is 2.2%.
Half-life of Rapolax is 57-63 hours.


Rapolax 1mg should be prescribed only by physicians who have experience with immunosuppression in organ transplant recipients and can supply necessary follow-up and appropriate checking
Usage in liver or lung transplantation as safety and efficacy is not established.
In liver transplant recipients have been noticed having high mortality, loss in graft, and hepatic artery thrombosis
In lung transplant recipients has been noticed Bronchial anastomotic dehiscence
Rapolax 1mg will have high risk of infection, lymphoma, and other malignancies due to raise immunosuppression
Greatest enhance sun exposure due to increased skin cancer risk
Patients generally presents with hemiparesis, apathy, confusion, cognitive deficiencies, and ataxia will have resulted Progressive multifocal leukoencephalopathy (PML), sometimes fatal


Rapolax co administration with cyclosporine will increases sirolimus concentration. Hence sirolimus should give 4 hours after administration of cyclosporine
Avoid co administration of Rapolax with strong inducers and strong inhibitors will decrease interaction potential with sirolimus
Using with grapefruit juice will blocks the CY3A4 – mediated metabolism of Rapolax. Avoid during using with sirolimus


hypersensitivity to sirolimus


If dose is missed to take, have immediately before next dose reaches or skip the dose and follow normal timing.
Please Consult with the doctor.


Rapolax 1mg Stored at 20℃-25℃
Avoid using if blister is torn or broken.


Common side effects :
Fever, cold and cough
Mouth sores;
Nausea, stomach pain, diarrhoea;
Headache, muscle aches;
Chest pain;
Dizziness; or
Other side effects, if it occurs then immediately call doctor :
Slow healing of a skin wound;
A new skin lesion,
Unusual bleeding
Sudden discomfort in chest, cough, feeling short of breath;
Pain around the transplanted kidney;
Infection like--fever, chills, painful mouth sores, skin sores, cold or flu symptoms, pain or burning when you urinate; or Anemia- skin in pale, unusual weakness, feeling light-headed or Dyspnea cold hands and feet.

We'd Like to Hear From You!


1., a fully licensed and regulated pharmacy, takes all precautions to strictly abide by the laws and regulations set forth in the dispensing of prescription medications. By placing the order for your prescription medicines, you acknowledge and accept the following terms regarding the purchase of any prescription medicines.
2. will not dispense any prescription medication without a valid prescription from a licensed physician.
3. If you are ordering prescription medication(s), you hereby confirm that you will send us a scanned copy of your valid prescription(s) via email, fax, Whatsapp, or by post, and this prescription shall then be subject to the scrutiny of and approval by our qualified Pharmacists.
4. The drug information provided in the is for informative purposes only and this Website is not intended to provide diagnosis, treatment or medical advice. We are not liable for any adverse effects or harm to you as a result of your reliance on the information in the Website.
5. requires either the User or Customer or the Caregiver to confirm he/she is completely aware of the indications, side effects, drug interactions, effects of missed dose or overdose of the medicines he/she orders from us. It is imperative to seek professional advice from your physician before purchasing or consuming any medicine from
6. At, a Caregiver can order prescription medicines on your behalf.

This information should not be used to decide whether to accept this product or any other medicine. Only a health care provider is knowledge and training to decide that a medicine suitable for a specific patient. This information does not support any drug as safe, are effective or approved for the treatment of any patient or health condition. It's simple a brief overview of general information about this product. It does not include all information on possible applications, indications, warnings, precautions, interactions, adverse effects or risks that may be relevant to this product. This information is not specific medical advice and does not replace information obtained from your health care provider. You should check with your health care provider for complete information about the risks and benefits of using this product.